The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Subscribe To Our Newsletter & Stay Updated
